Vanda Pharmaceuticals Inc. (VNDA) News
Filter VNDA News Items
VNDA News Results
|Loading, please wait...|
VNDA News Highlights
- VNDA's 30 day story count now stands at 2.
- Over the past 1 day, the trend for VNDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VNDA News From Around the Web
Below are the latest news stories about Vanda Pharmaceuticals Inc that investors may wish to consider to help them evaluate VNDA as an investment opportunity.
Investors in Vanda Pharmaceuticals (NASDAQ:VNDA) have made a decent return of 66% over the past year
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board, will take part in a virtual fireside chat at 1:30 PM ET.
Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aranthan S. Jones Ii, Chief Corporate Affairs Officer at Vanda Pharmaceuticals (NASDAQ:VNDA), made a large buy and sell of company shares on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aranthan S. Jones Ii purchased 12,119 Vanda Pharmaceuticals shares at prices ranging from $11.32 to $12.27 per share for a total of $141,250 on September 15. They then sold their shares on the same day in the open market.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021. Vanda management will host investor meetings. Vanda has updated its corporate presentation, which may be accessed on Vanda's website, www.vandapharma.com, by clicking on the Investors tab and following the Corporate Presentation link.
Should Weakness in Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
It is hard to get excited after looking at Vanda Pharmaceuticals' (NASDAQ:VNDA) recent performance, when its stock has...
(RTTNews) - Novavax, Inc. (NVAX) announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer and Treasurer. Kelly joins Novavax from Supernus Pharmaceuticals, where he served as CFO. Previously, he was CFO and Treasurer at Vanda Pharmaceuticals. The company also appointed Nasir Egal as Senior Vice President,
By Gina Lee
Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.